FDA Recommends Against Hydrocodone Rescheduling
The FDA announced that it will recommend that hydrocodone-containing products not be moved from Schedule III to Schedule II. DEA believes that rescheduling would reduce abuse of the drug. In recommending against rescheduling, the FDA said that more emergency room visits occur with oxycodone products than with hydrocodone. The FDA also expressed concern that movement of hydrocodone-containing products to Schedule II could lead to the use of more NSAID products as well as Schedule II opioid products. NCPA will be providing testimony opposing the rescheduling of hydrocodone containing products when the FDA holds a public hearing regarding this topic in
Catastrophic Storm Sandy
Our thoughts are with all of you impacted by this storm. We pray that you, your families and other loved ones are safe. Hitesh (Tesh) Patel, CEO, Trinity Apothecary
How Prescription Medications Are Priced?
The majority of patients are unaware of what prescription drugs actually cost. They know the amount of the co-pay they hand over each month, but they have no idea what it costs your pharmacy to obtain, safely dispense and get reimbursed for their medications. This lack of awareness by patients creates a misconception that can be detrimental to their health, and clouds the general understanding of the value of medication therapy in an overall health plan design. Patients don’t know the specifics about the current reimbursement model in which your pharmacy is required to participate. They don’t know that after submitting a